ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly retevmo (selpercatinib) — Worldwide revenue YoY (%) [legacy] (%)
Form 10-Q / 10-K MD&A (through FY2023)
Latest, Q4 2023
14.0%
Period ended Dec 31, 2023
Change on a year earlier
-53.0 pts
67.0% in Q4 2022
History
7 quarters
Since Q2 2022
Sources
7
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Retevmo (selpercatinib) — Worldwide revenue YoY (%) [legacy] (%) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | 14.0% | -53.0 pts | Earnings Release (Form 8-K FY2023Q4 EX-99.1) (filed 2024-02-06) ↗ |
| Q3 2023 | Sep 30, 2023 | 56.0% | +35.0 pts | Earnings Release (Form 8-K FY2023Q3 EX-99.1) (filed 2023-11-02) ↗ |
| Q2 2023 | Jun 30, 2023 | 45.0% | -30.0 pts | Earnings Release (Form 8-K FY2023Q2 EX-99.1) (filed 2023-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 23.0% | – | Earnings Release (Form 8-K FY2023Q1 EX-99.1) (filed 2023-04-27) ↗ |
| Q4 2022 | Dec 31, 2022 | 67.0% | – | Earnings Release (Form 8-K FY2022Q4 EX-99.1) (filed 2023-02-02) ↗ |
| Q3 2022 | Sep 30, 2022 | 21.0% | – | Earnings Release (Form 8-K FY2022Q3 EX-99.1) (filed 2022-11-01) ↗ |
| Q2 2022 | Jun 30, 2022 | 75.0% | – | Earnings Release (Form 8-K FY2022Q2 EX-99.1) (filed 2022-08-04) ↗ |
Cite this data
StockData. (2026). Eli Lilly Retevmo (selpercatinib) — Worldwide revenue YoY (%) [legacy] (%), quarterly Q2 2022–Q4 2023 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med_retevmo_yoy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.